This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Are Medical Stocks Lagging OrganiGram (OGI) This Year?
by Zacks Equity Research
Here is how OrganiGram (OGI) and ResMed (RMD) have performed compared to their sector so far this year.
Why OrganiGram (OGI) Might Surprise This Earnings Season
by Zacks Equity Research
OrganiGram (OGI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Rockwell Medical (RMTI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 41.67% and 0.43%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Organigram (OGI) Grows in Cannabis Space With SHRED X Heavies
by Zacks Equity Research
Organigram's (OGI) SHRED X Heavies is not only the first infused pre-roll in the SHRED product portfolio but also joins a lineup of value-driven, convenient and bold-flavored offerings.
Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -91.67% and 10.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in SurModics (SRDX): Can Its 16.1% Jump Turn into More Strength?
by Zacks Equity Research
SurModics (SRDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Stryker (SYK) Moves 4.2% Higher: Will This Strength Last?
by Zacks Equity Research
Stryker (SYK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
High Tide Inc. (HITI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
High Tide Inc. (HITI) delivered earnings and revenue surprises of 75% and 2.70%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of -100% and 9.74%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
OraSure (OSUR) Stock Jumps 9.3%: Will It Continue to Soar?
by Zacks Equity Research
OraSure (OSUR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
OrganiGram (OGI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 1.43%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
OrganiGram (OGI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
OrganiGram (OGI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akerna Corp. (KERN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akerna Corp. (KERN) delivered earnings and revenue surprises of -13.33% and 4.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ThermoGenesis Holdings, Inc. (THMO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -233.33% and 28.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Veru Inc. (VERU): Can Its 39.5% Jump Turn into More Strength?
by Zacks Equity Research
Veru Inc. (VERU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Envista (NVST) Q3 Earnings Match Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 0% and 0.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OrganiGram (OGI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of -50% and 5.67%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
High Tide Inc. (HITI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
High Tide Inc. (HITI) delivered earnings and revenue surprises of -175% and 3.49%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
OrganiGram (OGI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.15%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
Will OrganiGram (OGI) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
OrganiGram (OGI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neogen (NEOG) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -13.33% and 1.35%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
Akerna Corp. (KERN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akerna Corp. (KERN) delivered earnings and revenue surprises of -14.29% and 22.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OrganiGram (OGI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.44%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
Will OrganiGram (OGI) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
OrganiGram (OGI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OrganiGram (OGI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of -75% and 3.22%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?